Brief: Medicinova Announces Completion Of Enrollment In The Phase 2 Clinical Trial Evaluating Mn-166 (Ibudilast)
13/01/2023 24:12
Jan 12 (Reuters) - MediciNova Inc MNOV.O :
* MEDICINOVA ANNOUNCES COMPLETION OF ENROLLMENT IN THE PHASE
2
CLINICAL TRIAL EVALUATING MN-166 (IBUDILAST) FOR TREATMENT OF
RECURRENT AND NEWLY DIAGNOSED GLIOBLASTOMA
Source text for Eikon: ID:nGNX23jkQD
Further company coverage: MNOV.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Medicinova
See all newsBrief: 3D Investment Partners Cuts Stake In Medicinova To 9.88% From 11.22%, Filing Shows
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX
MediciNova falls as fatty liver drug misses significance on blood-fat reduction
US STOCKS ON THE MOVE-WhiteHawk, Nvidia, Snowflake